Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …

Viral diseases represent a major public health concerns and ever-present risks for
developing into future pandemics. Antiviral antibody therapeutics, either alone or in …

COVID‐19 vaccines prevent severe forms of the disease, but do not warrant complete
protection against breakthrough infections. This could be due to suboptimal mucosal …

Viral vectors have emerged as powerful tools for delivering and expressing foreign genes,
playing a pivotal role in gene therapy. Among these vectors, cytomegalovirus (CMV) stands …

An influenza vaccine approach that overcomes the problem of viral sequence diversity and
provides long-lived heterosubtypic protection is urgently needed to protect against …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes several host
proteases to cleave the spike (S) protein to enter host cells. SARS-CoV-2 S protein is …

Viral vector vaccine represents one of the important research directions of novel vaccines.
Viral vectors can efficiently deliver foreign genes and drive robust transgene expression in …

Current vaccines against COVID-19 elicit immune responses that are overall strong but
wane rapidly. As a consequence, the necessary booster shots have contributed to vaccine …

Herpesviruses are large DNA viruses that have long been used as powerful gene therapy
tools. In recent years, the ability of herpesviruses to stimulate both innate and adaptive …

A universal vaccine that generally prevents influenza virus infection and/or illness remains
elusive. We have been exploring a novel approach to vaccination involving replication …